Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

ot be treated with Reclast.

If you have HCM, you should drink plenty of clear fluids before using ZOMETA. If you have kidney problems, tell your doctor. The risk of adverse reactions (especially related to the kidney) may be greater for you. ZOMETA treatment is not for patients with severe kidney problems. Patients with kidney problems on multiple cycles of ZOMETA or other bisphosphonates are at greater risk for further kidney problems. It is important to get your blood tests while you are receiving ZOMETA. Your doctor will monitor your kidney function before each dose. Tell your doctor if you are on other drugs, including aminoglycosides, loop diuretics, and drugs which may be harmful to the kidney.

Osteonecrosis of the jaw (ONJ) has been reported mainly in cancer patients treated with intravenous bisphosphonates, including ZOMETA. Many of these patients were also receiving anti-cancer drugs and corticosteroids, which may make it more likely to get ONJ. If you have advanced breast cancer or a type of cancer called multiple myeloma, or if you have had dental extraction, periodontal disease, local trauma, including poorly fitting dentures, you may be at greater risk of getting ONJ. Many reports of ONJ involved patients with signs of local infection, including bone/bone marrow inflammation. You should maintain good oral hygiene and have a dental examination with preventive dentistry prior to beginning ZOMETA. While on treatment, avoid invasive dental procedures, if possible, as recovery may take longer. If you develop ONJ while on bisphosphonate therapy, dental surgery may worsen the condition. If you require dental procedures, there are no data available to suggest whether stopping ZOMETA treatment reduces the risk of ONJ. A causal relationship between bisphosphonate use and ONJ has not been established. Based on your condition, your doctor will determine the treatment plan you will receive.

Do not use ZOMETA if you are pregnant or plan to becom
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
9. Novartis Class Awarded $250 Million in Punitive Damages
10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... (PRWEB) August 31, 2014 This ... current state of the Epoxy Hardener industry ... basic overview of the industry, including definitions, applications ... Chinese domestic market analysis are provided with a ... of the market. A comparison between the international ...
(Date:8/29/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... difficult to manufacture proteins including biosimilar therapeutics, today ... for the second quarter ended June 30, 2014. ... initial public offering, we have the capital to ... from our proprietary protein expression platform," stated Bertrand ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 The ... $5.6 billion in 2019. It is expected to ... to 2019, and was valued at $1.8 billion ... by Transparency Market Research. , For more information ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled “Companion ...
(Date:8/29/2014)... Pittcon is pleased to announce that the ... Horiba Scientific, have organized a session on nanotechnology for ... , Asia’s largest analytical and scientific instruments show, will ... , The four speakers in this U.S. symposium, ... to Single Cells” will present their use of nanotechnology ...
Breaking Biology Technology:Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2
... Aug. 15 BioMaxx Systems Inc. (Other,OTC: BMXSF), ... engagement letter with,Alcofuel Technologies Ltd., for the provision ... micro-refinery. Pursuant to the engagement,letter, Alcofuel Technologies has ... engagement letter, to design and manufacture a small,scale ...
... Inc. (Nasdaq: ADLS ), today announced that ... informed the Company that the,market value of its ... days, which is the requirement for continued listing ... 4450(b)(1)(A). Nasdaq,also informed the Company that it is ...
... - AEterna Zentaris Inc.,(TSX: AEZ; NASDAQ: AEZS), a ... today announced the filling of a key,position completing ... Blake,M.D., as Senior Vice President and Chief Medical ... timely and critical as our foremost,priority is to ...
Cached Biology Technology:BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery 2Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 2Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 3Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter 4AEterna Zentaris completes management team with the appointment of Chief Medical Officer 2AEterna Zentaris completes management team with the appointment of Chief Medical Officer 3
(Date:9/2/2014)... American Society of Human Genetics (ASHG) and the ... the National Institutes of Health, have named Katherine ... in Chicago, the newest ASHG/NHGRI Genetics and Public ... The Genetics and Public Policy Fellowship is intended ... genetics-related health and research policy at a national ...
(Date:9/2/2014)... published paper provides a history of scientific research ... wildlife in these systems, and sets an agenda ... , The paper, "Mountain gloom and mountain glory ... change in mountain regions," appears online in the ... Charles C. Chester of Tufts University, Jodi A. ...
(Date:9/2/2014)... A team of University of Maryland physicists has ... scientists say make possible new nanostructures and nanotechnologies ... and quantum computing advances to new sensor development. ... Nature Communications the Maryland scientists, primary ... hybrid nanostructures that uses a connector, or "intermedium," ...
Breaking Biology News(10 mins):ASHG and NHGRI award genetics and public policy fellowship 2An uphill climb for mountain species? 2An uphill climb for mountain species? 3New synthesis method may shape future of nanostructures, clean energy 2New synthesis method may shape future of nanostructures, clean energy 3
... Darwin based his groundbreaking theory of natural selection on ... key to evolution. Some individuals are better adapted ... likely to survive and pass on their genes to ... the first place still poses somewhat of a puzzle ...
... Springer to publish its official English-language journal, Human Cell ... published at Springer in early 2011. The journal was ... as a forum for international research on all aspects of ... of studies using ES/iPS cells or tissue stem cells derived ...
... study shows for the first time that the three ... disrupt a molecular network that includes several important genes ... research was led by investigators at the Ohio State ... Hospital and Richard J. Solove Research Institute (OSUCCC ...
Cached Biology News:Evolution by mistake 2Evolution by mistake 3Evolution by mistake 4Human Cell joins Springer's publishing program 2Molecular network influences development of chronic lymphocytic leukemia 2
ANTI-RAT ADHESION MARKERS, CDs, CYTOKINES, ETC Rat ICAM PE - Mouse IgG1...
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
Reacts with methylated DNA from plants and vertebrates...
Rabbit polyclonal to Bag5 ( Abpromise for all tested applications). entrezGeneID: 9529 SwissProtID: Q9UL15...
Biology Products: